ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
Company to host corporate update webcast to share results on December 11, 2024
公司将于2024年12月11日举行企业更新网络研讨会，分享成果
LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
瑞士洛桑，2024年12月6日 / PRNewswire / - adc therapeutics SA（纽交所：adct）今日宣布，将于2024年12月11日上午8:30举办电话会议和现场网络直播，以更新LOTIS-7阶段10亿开放标签临床试验的初步数据，该试验评估了在复发性或难治性弥漫大b细胞淋巴瘤（r / r DLBCL）患者中，ZYNLONTA与双特异性抗体glofitamab（COLUMVI）联合使用的安全性和有效性。
To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
要参加电话会议，请在此注册。北美和加拿大的参与者免费拨打电话号码为1-800-836-8184。建议您在活动开始前10分钟加入，尽管您可以随时进行预先注册。电话会议的实时网络直播将在 adc therapeutics 网站的投资者部分“事件和演示文稿”下提供，网址为ir.adctherapeutics.com。电话会议后，网络直播将保留30天。
About ADC Therapeutics
关于ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics（纽交所：ADCT）是一家商业化阶段的全球领先者和先锋，致力于抗体药物结合物（ADCs）领域。公司正在推进其专有ADC技术，改变对患有血液恶性肿瘤和实体瘤患者的治疗范式。
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics的CD19-定向ADC ZYNLONTA (loncastuximab tesirine-lpyl) 已获得FDA的加速批准和欧洲委员会的有条件批准，用于治疗两条或以上全身疗法经治疗失败或复发性弥漫大B细胞淋巴瘤。ZYNLONTA还在与其他药物联用及早期治疗方案的开发中。除了ZYNLONTA外，ADC Therapeutics还有多个ADC正在进行临床和临床前开发。
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn.
adc therapeutics 总部位于瑞士洛桑（Biopôle），在伦敦和新泽西设有运营。欲了解更多信息，请访问 并在社交媒体上关注公司。LinkedIn.
ZYNLONTA is a registered trademark of ADC Therapeutics SA.
ZYNLONTA是adc therapeutics SA的注册商标。
CONTACTS:
联系方式：
Investors
Marcy Graham
ADC Therapeutics
[email protected]
+1 650-667-6450
投资者
马西·格雷厄姆
ADC Therapeutics
[email protected]
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040
媒体
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040
SOURCE ADC Therapeutics SA
adc therapeutics SA来源
